|
PH12013501201A1
(en)
*
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
WO2013059593A1
(en)
|
2011-10-20 |
2013-04-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-cd22 chimeric antigen receptors
|
|
KR102437522B1
(ko)
*
|
2012-05-25 |
2022-08-26 |
셀렉티스 |
면역요법을 위한 동종이형 및 면역억제제 저항성인 ｔ 세포의 조작 방법
|
|
EP4310191A3
(en)
|
2012-06-14 |
2024-05-15 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule containing modified fc region
|
|
CN104822705B
(zh)
*
|
2012-10-24 |
2019-07-12 |
美国卫生和人力服务部 |
M971嵌合抗原受体
|
|
EP2934532B1
(en)
|
2012-12-20 |
2019-10-23 |
Purdue Research Foundation |
Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
|
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
|
DK2958943T3
(da)
|
2013-02-20 |
2019-12-09 |
Univ Pennsylvania |
Behandling af cancer ved anvendelse af humaniseret anti-EGFRvIII kimær antigenreceptor
|
|
TW201446794A
(zh)
|
2013-02-20 |
2014-12-16 |
Novartis Ag |
利用抗－ｃｄ１２３嵌合抗原受體工程化ｔ細胞之初級人類白血病有效靶向
|
|
AU2014240083C1
(en)
|
2013-03-15 |
2019-10-24 |
Celgene Corporation |
Modified T lymphocytes
|
|
EP2970426B1
(en)
|
2013-03-15 |
2019-08-28 |
Michael C. Milone |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
|
WO2014160627A1
(en)
|
2013-03-25 |
2014-10-02 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-cd276 polypeptides, proteins, and chimeric antigen receptors
|
|
US11077144B2
(en)
|
2013-05-13 |
2021-08-03 |
Cellectis |
CD19 specific chimeric antigen receptor and uses thereof
|
|
EP3783098A1
(en)
|
2013-05-14 |
2021-02-24 |
Board Of Regents, The University Of Texas System |
Human application of engineered chimeric antigen receptor (car) t-cells
|
|
AU2014268364A1
(en)
|
2013-05-24 |
2015-12-10 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptor-targeting monoclonal antibodies
|
|
KR102271498B1
(ko)
|
2013-08-30 |
2021-07-05 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
종양 치료를 위한 키누레닌 고갈 효소의 투여
|
|
CN105813654B
(zh)
|
2013-10-11 |
2019-05-31 |
美国政府(由卫生和人类服务部的部长所代表) |
Tem8抗体及其用途
|
|
WO2015069922A2
(en)
|
2013-11-06 |
2015-05-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Alk antibodies, conjugates, and chimeric antigen receptors, and their use
|
|
CN103589742A
(zh)
*
|
2013-11-07 |
2014-02-19 |
申峰 |
嵌合体抗原受体胞内段的基因及其编码蛋白
|
|
TWI712421B
(zh)
|
2013-11-11 |
2020-12-11 |
日商中外製藥股份有限公司 |
含改變的抗體可變區之抗原結合分子
|
|
US10246505B2
(en)
|
2013-11-25 |
2019-04-02 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric antigen receptors to control HIV infection
|
|
ES2918501T3
(es)
|
2013-12-19 |
2022-07-18 |
Novartis Ag |
Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
|
|
US10287354B2
(en)
|
2013-12-20 |
2019-05-14 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
|
WO2015103549A1
(en)
|
2014-01-03 |
2015-07-09 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
|
US11028143B2
(en)
|
2014-01-21 |
2021-06-08 |
Novartis Ag |
Enhanced antigen presenting ability of RNA CAR T cells by co-introduction of costimulatory molecules
|
|
WO2015120187A1
(en)
|
2014-02-05 |
2015-08-13 |
The University Of Chicago |
Chimeric antigen receptors recognizing cancer-spevific tn glycopeptide variants
|
|
EP3656864A1
(en)
|
2014-02-14 |
2020-05-27 |
Board of Regents, The University of Texas System |
Chimeric antigen receptors and methods of making
|
|
CN106279434B
(zh)
*
|
2014-02-24 |
2020-07-03 |
西比曼生物科技（上海）有限公司 |
工程化cd20靶向性的nkt细胞及其制备方法和应用
|
|
AU2015244039B2
(en)
|
2014-04-07 |
2021-10-21 |
Novartis Ag |
Treatment of cancer using anti-CD19 chimeric antigen receptor
|
|
CA2945320A1
(en)
|
2014-04-10 |
2015-10-15 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Drug regulated transgene expression
|
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
TWI750110B
(zh)
|
2014-07-21 |
2021-12-21 |
瑞士商諾華公司 |
使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症
|
|
SG10201913765YA
(en)
|
2014-07-21 |
2020-03-30 |
Novartis Ag |
Treatment of cancer using a cd33 chimeric antigen receptor
|
|
KR20170037625A
(ko)
|
2014-07-21 |
2017-04-04 |
노파르티스 아게 |
Cll-1 키메라 항원 수용체를 사용한 암의 치료
|
|
KR102048855B1
(ko)
*
|
2014-07-29 |
2019-11-26 |
셀렉티스 |
암 면역요법을 위한 ror1(ntrkr1) 특이적 키메라 항원 수용체
|
|
ES2791248T3
(es)
|
2014-08-19 |
2020-11-03 |
Novartis Ag |
Receptor antigénico quimérico (CAR) anti-CD123 para su uso en el tratamiento del cáncer
|
|
JP7080053B2
(ja)
|
2014-08-29 |
2022-06-03 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
腫瘍の治療のための、キヌレニンを枯渇させる酵素の投与
|
|
ES2777305T5
(en)
|
2014-09-04 |
2025-09-30 |
Cellectis |
Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy
|
|
JP6613304B2
(ja)
|
2014-09-17 |
2019-12-04 |
ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
抗ｃｄ２７６抗体（ｂ７ｈ３）
|
|
KR20250067191A
(ko)
|
2014-09-17 |
2025-05-14 |
노파르티스 아게 |
입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화
|
|
KR20170068504A
(ko)
|
2014-10-08 |
2017-06-19 |
노파르티스 아게 |
키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도
|
|
ES2753391T3
(es)
|
2014-10-14 |
2020-04-08 |
Halozyme Inc |
Composiciones de adenosina desaminasa 2 (ADA2), variantes de la misma y métodos de uso de las mismas
|
|
AU2015343013B2
(en)
*
|
2014-11-05 |
2020-07-16 |
Board Of Regents, The University Of Texas System |
Gene modified immune effector cells and engineered cells for expansion of immune effector cells
|
|
CA2964783C
(en)
|
2014-11-05 |
2024-01-23 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptors (car) to selectively target protein complexes
|
|
TWI880146B
(zh)
|
2014-11-11 |
2025-04-11 |
日商中外製藥股份有限公司 |
包含經改變之抗體可變區之抗原結合分子的資料庫
|
|
CA2969456A1
(en)
|
2014-12-03 |
2016-06-09 |
Juno Therapeutics, Inc. |
Methods and compositions for adoptive cell therapy
|
|
CN113968913A
(zh)
|
2014-12-08 |
2022-01-25 |
美国卫生和人力服务部 |
抗cd70嵌合抗原受体
|
|
KR102376244B1
(ko)
|
2014-12-24 |
2022-03-21 |
오토러스 리미티드 |
세포
|
|
CA3197849A1
(en)
|
2014-12-29 |
2016-07-07 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
WO2016115482A1
(en)
|
2015-01-16 |
2016-07-21 |
Novartis Pharma Ag |
Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor
|
|
WO2016123143A1
(en)
|
2015-01-26 |
2016-08-04 |
The University Of Chicago |
CAR T-CELLS RECOGNIZING CANCER-SPECIFIC IL 13Rα2
|
|
ES2869972T3
(es)
|
2015-01-26 |
2021-10-26 |
Cellectis |
Sistemas de receptores de antígenos quiméricos dirigidos por mAb para clasificar/agotar células inmunitarias genomanipuladas
|
|
JP7264592B2
(ja)
|
2015-01-26 |
2023-04-25 |
ザ ユニバーシティー オブ シカゴ |
ＩＬ１３Ｒα２結合剤及び癌治療におけるその使用
|
|
WO2016123578A1
(en)
|
2015-01-30 |
2016-08-04 |
The Regents Of The University Of California |
Protein delivery in primary hematopoietic cells
|
|
US11161907B2
(en)
|
2015-02-02 |
2021-11-02 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
JP6724023B2
(ja)
|
2015-02-09 |
2020-07-15 |
リサーチ ディベロップメント ファウンデーション |
改善された補体活性化を示す操作された免疫グロブリンｆｃポリペプチド
|
|
US10738116B2
(en)
|
2015-03-19 |
2020-08-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Dual specific anti-CD22-anti-CD19 chimeric antigen receptors
|
|
ES2789348T3
(es)
|
2015-03-20 |
2020-10-26 |
Us Health |
Anticuerpos neutralizantes para GP120 y sus usos
|
|
MX2017012939A
(es)
*
|
2015-04-08 |
2018-05-22 |
Novartis Ag |
Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
|
|
SG11201708516YA
(en)
|
2015-04-17 |
2017-11-29 |
David Maxwell Barrett |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
|
EP3286211A1
(en)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
GB201507111D0
(en)
*
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic acid construct
|
|
EP4424326A3
(en)
|
2015-06-10 |
2024-11-13 |
ImmunityBio, Inc. |
Modified nk-92 cells for treating cancer
|
|
FI3909972T3
(fi)
|
2015-06-19 |
2024-05-03 |
Sebastian Kobold |
Pd1-cd28-fuusioproteiineja ja niiden käyttö lääkkeessä
|
|
WO2016210447A1
(en)
|
2015-06-26 |
2016-12-29 |
University Of Southern California |
Masking chimeric antigen receptor t cells for tumor-specific activation
|
|
AU2016297014B2
(en)
|
2015-07-21 |
2021-06-17 |
Novartis Ag |
Methods for improving the efficacy and expansion of immune cells
|
|
EP3331913A1
(en)
|
2015-08-07 |
2018-06-13 |
Novartis AG |
Treatment of cancer using chimeric cd3 receptor proteins
|
|
US11098283B2
(en)
|
2015-08-25 |
2021-08-24 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
T cells modified to overexpress c-Myb
|
|
US10526408B2
(en)
|
2015-08-28 |
2020-01-07 |
Research Development Foundation |
Engineered antibody FC variants
|
|
JP6905163B2
(ja)
|
2015-09-03 |
2021-07-21 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
サイトカイン放出症候群を予測するバイオマーカー
|
|
WO2017044699A1
(en)
*
|
2015-09-10 |
2017-03-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-cd276 chimeric antigen receptors
|
|
AU2016335750B2
(en)
|
2015-10-07 |
2023-05-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia
|
|
AU2016336868B2
(en)
|
2015-10-16 |
2022-04-14 |
Ludwig-Maximilians-Universität München |
CXCR6-transduced T cells for targeted tumor therapy
|
|
WO2017070042A1
(en)
|
2015-10-20 |
2017-04-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of producing t cell populations using akt inhibitors
|
|
US11059879B2
(en)
|
2015-10-27 |
2021-07-13 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptor molecules and uses thereof
|
|
EA201891338A1
(ru)
|
2015-12-04 |
2018-12-28 |
Новартис Аг |
Композиции и способы для иммуноонкологии
|
|
EP3393504B1
(en)
|
2015-12-22 |
2025-09-24 |
Novartis AG |
Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
|
|
WO2017139199A1
(en)
|
2016-02-10 |
2017-08-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Inducible arginase
|
|
US11542486B2
(en)
|
2016-03-02 |
2023-01-03 |
Board Of Regents, The University Of Texas System |
Human kynureninase enzyme variants having improved pharmacological properties
|
|
US11549099B2
(en)
|
2016-03-23 |
2023-01-10 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
|
JP7282521B2
(ja)
|
2016-04-08 |
2023-05-29 |
パーデュー・リサーチ・ファウンデイション |
Ｃａｒ ｔ細胞療法のための方法および組成物
|
|
EP3443001B1
(en)
|
2016-04-11 |
2025-04-30 |
Obsidian Therapeutics, Inc. |
REGULATED BIOCIRCUIT SYSTEMS
|
|
CN107298715B
(zh)
*
|
2016-04-15 |
2021-05-04 |
阿思科力(苏州)生物科技有限公司 |
Slit2D2-嵌合抗原受体及其应用
|
|
CN105968210B
(zh)
*
|
2016-05-13 |
2019-05-31 |
深圳生创精准医疗科技有限公司 |
靶向cd22的强杀伤性嵌合抗原受体t细胞及其在制备治疗肿瘤的药物中的用途
|
|
CN106167527A
(zh)
*
|
2016-06-13 |
2016-11-30 |
长沙郝怡雅医药科技有限公司 |
一种融合蛋白
|
|
GB201610512D0
(en)
*
|
2016-06-16 |
2016-08-03 |
Autolus Ltd |
Chimeric antigen receptor
|
|
CN109476749A
(zh)
|
2016-06-30 |
2019-03-15 |
豪夫迈·罗氏有限公司 |
改良的过继性t细胞疗法
|
|
CA3037518A1
(en)
|
2016-09-21 |
2018-03-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric antigen receptor (car) that targets chemokine receptor ccr4 and its use
|
|
US11976299B2
(en)
|
2016-09-23 |
2024-05-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of preparing an isolated population of dendritic cells and methods of treating cancer using same
|
|
WO2018064594A2
(en)
|
2016-09-29 |
2018-04-05 |
Nantkwest, Inc. |
Hla class i-deficient nk-92 cells with decreased immunogenicity
|
|
EP3523331A1
(en)
|
2016-10-07 |
2019-08-14 |
Novartis AG |
Chimeric antigen receptors for the treatment of cancer
|
|
BR112019006652A2
(pt)
|
2016-10-13 |
2019-07-02 |
Juno Therapeutics Inc |
métodos e composições para imunoterapia envolvendo moduladores da via metabólica do triptofano
|
|
CN107964549B
(zh)
*
|
2016-10-20 |
2020-12-08 |
上海恒润达生生物科技有限公司 |
靶向cd22的嵌合抗原受体及其用途
|
|
WO2018075820A2
(en)
|
2016-10-20 |
2018-04-26 |
Celgene Corporation |
Cereblon-based heterodimerizable chimeric antigen receptors
|
|
WO2018111981A1
(en)
|
2016-12-13 |
2018-06-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of preparing an isolated or purified population of thymic emigrant cells and methods of treatment using same
|
|
KR102528384B1
(ko)
|
2017-01-06 |
2023-05-02 |
이뮤너티바이오, 인크. |
감소된 cd96/tigit 발현을 갖는 유전자 변형된 nk-92 세포
|
|
CA3096798C
(en)
|
2017-01-09 |
2026-02-24 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Compositions and methods for treating cancer with anti-mesothelin immunotherapy
|
|
EP4043485A1
(en)
|
2017-01-26 |
2022-08-17 |
Novartis AG |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
|
CN110612119B
(zh)
|
2017-02-07 |
2024-10-29 |
西雅图儿童医院（Dba西雅图儿童研究所） |
磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂
|
|
IL268836B2
(en)
|
2017-02-24 |
2024-04-01 |
Macrogenics Inc |
Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
|
|
JP7178355B2
(ja)
|
2017-02-28 |
2022-11-25 |
エンドサイト・インコーポレイテッド |
Ｃａｒ ｔ細胞療法のための組成物および方法
|
|
CA3055200A1
(en)
|
2017-03-03 |
2018-09-07 |
Obsidian Therapeutics, Inc. |
Compositions and methods for immunotherapy
|
|
KR102746901B1
(ko)
*
|
2017-03-03 |
2024-12-26 |
옵시디안 테라퓨틱스, 인크. |
Cd19 조성물 및 면역요법을 위한 방법
|
|
US11629340B2
(en)
|
2017-03-03 |
2023-04-18 |
Obsidian Therapeutics, Inc. |
DHFR tunable protein regulation
|
|
WO2018175636A2
(en)
|
2017-03-22 |
2018-09-27 |
Novartis Ag |
Compositions and methods for immunooncology
|
|
US20210122831A1
(en)
*
|
2017-03-27 |
2021-04-29 |
Noile-Immune Biotech, Inc. |
Chimeric antigen receptor
|
|
EP4414380A3
(en)
|
2017-03-31 |
2024-12-04 |
Cellectis SA |
Universal anti-cd22 chimeric antigen receptor engineered immune cells
|
|
WO2018183888A2
(en)
|
2017-03-31 |
2018-10-04 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling
|
|
US11767512B2
(en)
|
2017-04-13 |
2023-09-26 |
Cellectis |
Sequence specific reagents targeting CCR5 in primary hematopoietic cells
|
|
WO2018195339A1
(en)
|
2017-04-19 |
2018-10-25 |
Board Of Regents, The University Of Texas System |
Immune cells expressing engineered antigen receptors
|
|
AU2018269194B2
(en)
|
2017-05-15 |
2025-05-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bicistronic chimeric antigen receptors and their uses
|
|
CA3065126A1
(en)
*
|
2017-06-01 |
2018-12-06 |
Innovative Cellular Therapeutics CO., LTD. |
Chimeric antigen receptor cell preparation and uses thereof
|
|
US12384830B2
(en)
|
2017-06-02 |
2025-08-12 |
Regents Of The University Of Minnesota |
Compositions and methods for improving immunotherapy
|
|
US11883431B2
(en)
|
2017-06-05 |
2024-01-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
T-cells modified to overexpress PHF19
|
|
WO2018237325A1
(en)
*
|
2017-06-22 |
2018-12-27 |
University Of Southern California |
Combination cancer therapy using chimeric antigen receptor engineered natural killer cells as chemotherapeutic drug carriers
|
|
US12144825B2
(en)
|
2017-06-30 |
2024-11-19 |
Cellectis |
Cellular immunotherapy for repetitive administration
|
|
US11235004B2
(en)
|
2017-06-30 |
2022-02-01 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Lymphocyte cell lines and uses thereof
|
|
WO2019060425A1
(en)
|
2017-09-19 |
2019-03-28 |
Massachusetts Institute Of Technology |
COMPOSITIONS FOR CHIMERIC ANTIGENIC RECEPTOR T CELL THERAPY AND USES THEREOF
|
|
WO2019075055A1
(en)
|
2017-10-11 |
2019-04-18 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
METHODS FOR PRODUCING T-CELL POPULATIONS USING P38 MAPK INHIBITORS
|
|
WO2019079249A1
(en)
*
|
2017-10-16 |
2019-04-25 |
Lentigen Technology, Inc. |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER WITH ANTI-CD22 IMMUNOTHERAPY
|
|
EP3697438A4
(en)
|
2017-10-18 |
2021-08-18 |
Intrexon Corporation |
POLYPEPTIDE COMPOSITIONS WITH SPACERS
|
|
JP7585034B2
(ja)
|
2017-10-18 |
2024-11-18 |
ノバルティス アーゲー |
選択的タンパク質分解のための組成物及び方法
|
|
WO2019084284A1
(en)
|
2017-10-27 |
2019-05-02 |
Coneksis, Inc. |
NK CELLS FOR USE IN THE TREATMENT OF CANCER IN DOGS
|
|
TW201938194A
(zh)
|
2017-12-05 |
2019-10-01 |
日商中外製藥股份有限公司 |
包含結合cd3及cd137的改變的抗體可變區之抗原結合分子
|
|
WO2019117976A1
(en)
|
2017-12-17 |
2019-06-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Peptide hydrogels and use thereof
|
|
TW201930591A
(zh)
|
2018-01-08 |
2019-08-01 |
瑞士商諾華公司 |
用於與嵌合抗原受體療法併用之免疫增強rna
|
|
JP7549303B2
(ja)
|
2018-01-22 |
2024-09-11 |
エンドサイト・インコーポレイテッド |
Ｃａｒ ｔ細胞の使用方法
|
|
US20210040451A1
(en)
|
2018-01-31 |
2021-02-11 |
Nantkwest, Inc. |
Use of 5% human albumin in wash and harvest media
|
|
SG11202007426XA
(en)
|
2018-02-06 |
2020-09-29 |
Seattle Childrens Hospital Dba Seattle Childrens Res Inst |
Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
|
|
EP3749770B9
(en)
|
2018-02-09 |
2025-12-17 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Tethered interleukin-15 and interleukin-21
|
|
CA3090791A1
(en)
|
2018-02-11 |
2019-08-15 |
Memorial Sloan-Kettering Cancer Center |
Non-hla restricted t cell receptors and uses thereof
|
|
JP7273421B2
(ja)
|
2018-02-21 |
2023-05-15 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用
|
|
CN112105382A
(zh)
|
2018-02-23 |
2020-12-18 |
恩多塞特公司 |
用于car t细胞疗法的顺序方法
|
|
MX2020009272A
(es)
|
2018-03-06 |
2021-01-08 |
Univ Pennsylvania |
Receptores de antígeno quimérico del antígeno de membrana específico de próstata y métodos de uso de los mismos.
|
|
CN112004829A
(zh)
|
2018-03-12 |
2020-11-27 |
南克维斯特公司 |
Cd33car修饰的高亲和力nk细胞(t-hank)用于降低髓系衍生的抑制细胞的抑制活性(或降低对nk细胞活性的负面影响)的用途
|
|
CA3095920A1
(en)
*
|
2018-04-10 |
2019-10-17 |
Amgen Inc. |
Chimeric receptors to dll3 and methods of use thereof
|
|
SG11202010116PA
(en)
|
2018-04-13 |
2020-11-27 |
Sangamo Therapeutics France |
Chimeric antigen receptor specific for interleukin-23 receptor
|
|
CA3096549A1
(en)
|
2018-04-16 |
2019-10-24 |
Board Of Regents, The University Of Texas System |
Human kynureninase enzymes and uses thereof
|
|
US12415845B2
(en)
|
2018-04-24 |
2025-09-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of producing T cell populations using hydroxycitric acid and/or a salt thereof
|
|
KR20210011977A
(ko)
|
2018-05-22 |
2021-02-02 |
난트케이웨스트, 인크. |
Nk-92 세포를 성장시키기 위한 기초 배지
|
|
AU2019272583B2
(en)
|
2018-05-22 |
2022-01-06 |
Immunitybio, Inc. |
Optimization of NK-92 cell growth using poloxamer
|
|
IL321548A
(en)
|
2018-05-22 |
2025-08-01 |
Immunitybio Inc |
Recombinant NK cells expressing a chimeric antigen receptor (CAR) for epsilon-FC and uses thereof
|
|
CA3100724A1
(en)
|
2018-06-13 |
2019-12-19 |
Novartis Ag |
B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof
|
|
US20210267190A1
(en)
|
2018-07-10 |
2021-09-02 |
Nantkwest, Inc. |
Cryopreservation
|
|
AU2019300782B2
(en)
|
2018-07-10 |
2023-12-21 |
Immunitybio, Inc. |
Generating CIK NKT cells from cord blood
|
|
EP3820903A1
(en)
|
2018-07-12 |
2021-05-19 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Affinity matured cd22-specific monoclonal antibody and uses thereof
|
|
WO2020028656A1
(en)
|
2018-08-01 |
2020-02-06 |
Nantkwest, Inc. |
A quadricistronic system comprising a homing receptor or a cytokine, and chimeric antigen receptor for genetic modification of immunotherapies
|
|
US12498363B2
(en)
|
2018-08-01 |
2025-12-16 |
Immunitybio, Inc. |
Combined invasion and cytotoxicity assay using chemokine secreting target cells
|
|
JP2021531808A
(ja)
|
2018-08-01 |
2021-11-25 |
イミュニティーバイオ インコーポレイテッド |
実証された標的に対する二次ホーミングの活性化を有する、ケモカイン応答性が活性化されたナチュラルキラー細胞
|
|
MX2021000827A
(es)
|
2018-08-03 |
2021-03-25 |
Chugai Pharmaceutical Co Ltd |
Molecula de union a antigeno que contiene dos dominios de union a antigeno que estan enlazados entre si.
|
|
CN109022363A
(zh)
*
|
2018-08-15 |
2018-12-18 |
马晓冬 |
一种基于PiggyBac载体的CD-133-CAR-T系统构建方法
|
|
EP3856763A1
(en)
|
2018-09-28 |
2021-08-04 |
Massachusetts Institute of Technology |
Collagen-localized immunomodulatory molecules and methods thereof
|
|
BR112021005472A2
(pt)
|
2018-09-28 |
2021-06-15 |
Chugai Seiyaku Kabushiki Kaisha |
molécula de ligação ao antígeno compreendendo uma região variável do anticorpo alterada
|
|
BR112021007690A2
(pt)
|
2018-10-22 |
2021-08-10 |
Shanghai GenBase Biotechnology Co., Ltd. |
anticorpo anti-cldn18.2 e uso do mesmo
|
|
US12109238B2
(en)
|
2018-11-06 |
2024-10-08 |
Immunitybio, Inc. |
Chimeric antigen receptor-modified NK-92 cells
|
|
IL316887A
(en)
|
2018-11-06 |
2025-01-01 |
Immunitybio Inc |
NK-92 cells with chimeric antigen receptor modification
|
|
EP3883585A4
(en)
*
|
2018-11-20 |
2022-12-14 |
Innovative Cellular Therapeutics Holdings, Ltd. |
MODIFIED CELL EXPRESSING THERAPEUTIC AND USES THEREOF
|
|
CN121518401A
(zh)
|
2018-11-26 |
2026-02-13 |
免疫生物公司 |
具有稳定的Fc受体表达的IL-2依赖性NK-92细胞
|
|
EP3670530A1
(en)
|
2018-12-18 |
2020-06-24 |
Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft |
Cd22-specific t cell receptors and adoptive t cell therapy for treatment of b cell malignancies
|
|
WO2020182681A1
(en)
|
2019-03-08 |
2020-09-17 |
Klinikum Der Universität München |
Ccr8 expressing lymphocytes for targeted tumor therapy
|
|
AU2020301413A1
(en)
|
2019-06-24 |
2022-02-10 |
Children's Hospital Los Angeles |
BCL11B overexpression to enhance human thymopoiesis T cell function
|
|
JP2022538974A
(ja)
|
2019-06-26 |
2022-09-07 |
マサチューセッツ インスチテュート オブ テクノロジー |
免疫調節融合タンパク質－金属水酸化物錯体およびその方法
|
|
WO2021003297A1
(en)
|
2019-07-02 |
2021-01-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that bind egfrviii and their use
|
|
WO2021009694A1
(en)
*
|
2019-07-17 |
2021-01-21 |
National University Of Singapore |
Functional binders synthesized and secreted by immune cells
|
|
CN113574169A
(zh)
|
2019-08-01 |
2021-10-29 |
南克维斯特公司 |
抗b7-h4嵌合抗原受体修饰的nk-92细胞
|
|
CA3150224A1
(en)
|
2019-09-10 |
2021-03-18 |
Obsidian Therapeutics, Inc. |
Ca2 compositions and methods for tunable regulation
|
|
JP2023501871A
(ja)
|
2019-09-20 |
2023-01-20 |
上海吉倍生物技術有限公司 |
Ｂｃｍａ標的化抗体及びキメラ抗原受容体
|
|
WO2021061648A1
(en)
|
2019-09-23 |
2021-04-01 |
Massachusetts Institute Of Technology |
Methods and compositions for stimulation of endogenous t cell responses
|
|
IL292924A
(en)
|
2019-11-26 |
2022-07-01 |
Novartis Ag |
Chimeric antigen receptors cd19 and cd22 and their uses
|
|
PH12022551291A1
(en)
|
2019-11-26 |
2023-11-20 |
Novartis Ag |
Chimeric antigen receptors binding bcma and cd19 and uses thereof
|
|
US11230699B2
(en)
|
2020-01-28 |
2022-01-25 |
Immunitybio, Inc. |
Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
|
|
AU2021217003A1
(en)
|
2020-02-04 |
2022-09-15 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Anti-dinitrophenol chimeric antigen receptors
|
|
KR20240096884A
(ko)
|
2020-03-10 |
2024-06-26 |
매사추세츠 인스티튜트 오브 테크놀로지 |
조작된 기억-유사 nk 세포 및 이의 조성물을 생성하기 위한 방법
|
|
US11896619B2
(en)
|
2020-03-10 |
2024-02-13 |
Massachusetts Institute Of Technology |
Compositions and methods for immunotherapy of NPM1c-positive cancer
|
|
TWI909146B
(zh)
|
2020-03-31 |
2025-12-21 |
日商中外製藥股份有限公司 |
Dll3靶向之多特異性抗原結合分子及其用途
|
|
US12448453B2
(en)
*
|
2020-04-02 |
2025-10-21 |
Nanjing IASO Biotechnology Co., Ltd. |
Fully human anti-human CD22 chimeric antigen receptor and application thereof
|
|
CN111484562B
(zh)
*
|
2020-04-25 |
2021-08-20 |
首都医科大学附属北京朝阳医院 |
一种靶向cd22蛋白的抗体、嵌合抗原受体和药物
|
|
US20210340524A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
|
US12433954B2
(en)
|
2020-05-01 |
2025-10-07 |
Massachusetts Institute Of Technology |
Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs
|
|
IL298558A
(en)
|
2020-05-27 |
2023-01-01 |
Antion Biosciences Sa |
Adapter molecules redirect CAR T cells to the antigen of interest
|
|
WO2022055946A1
(en)
|
2020-09-08 |
2022-03-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
T cell phenotypes associated with response to adoptive cell therapy
|
|
EP4243937A2
(en)
|
2020-11-13 |
2023-09-20 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Enhanced antigen reactivity of immune cells expressing a mutant non-signaling cd3 zeta chain
|
|
WO2022115492A1
(en)
|
2020-11-24 |
2022-06-02 |
Lyell Immunopharma, Inc. |
Methods for making, compositions comprising, and methods of using rejuvenated t cells
|
|
AU2021392032A1
(en)
|
2020-12-03 |
2023-06-22 |
Century Therapeutics, Inc. |
Genetically engineered cells and uses thereof
|
|
US11661459B2
(en)
|
2020-12-03 |
2023-05-30 |
Century Therapeutics, Inc. |
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
|
|
US12551584B1
(en)
|
2020-12-07 |
2026-02-17 |
Actinium Pharmaceuticals, Inc. |
Lewis Y radioimmunotherapy for the treatment of cancer
|
|
AR124414A1
(es)
|
2020-12-18 |
2023-03-22 |
Century Therapeutics Inc |
Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
|
|
CA3212530A1
(en)
|
2021-03-05 |
2022-09-09 |
Shanghai GenBase Biotechnology Co., Ltd. |
Anti-cldn6 antibody and use thereof
|
|
WO2022251070A1
(en)
*
|
2021-05-27 |
2022-12-01 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Modified chimeric antigen receptor and use thereof
|
|
WO2023021113A1
(en)
|
2021-08-18 |
2023-02-23 |
Julius-Maximilians-Universität Würzburg |
Hybrid tumor/cancer therapy based on targeting the resolution of or inducing transcription-replication conflicts (trcs)
|
|
US20260083848A1
(en)
|
2021-11-03 |
2026-03-26 |
Viracta Therapeutics, Inc. |
Combination of car t-cell therapy with btk inhibitors and methods of use thereof
|
|
WO2023130040A2
(en)
|
2021-12-31 |
2023-07-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
T cell therapy with vaccination as a combination immunotherapy against cancer
|
|
TW202340474A
(zh)
|
2022-01-11 |
2023-10-16 |
大陸商深圳市珈鈺生物科技有限公司 |
樹突細胞腫瘤疫苗和其用途
|
|
CN114774364B
(zh)
*
|
2022-04-26 |
2024-04-26 |
深圳市体内生物医药科技有限公司 |
一种嵌合抗原受体t细胞及其制备方法和应用
|
|
WO2023239940A1
(en)
|
2022-06-10 |
2023-12-14 |
Research Development Foundation |
Engineered fcriib selective igg1 fc variants and uses thereof
|
|
EP4653467A1
(en)
*
|
2023-01-19 |
2025-11-26 |
Wuhan Zhaozhi Biotechnology Co., Ltd. |
Car molecule, cell or exosome containing same, and use thereof
|
|
WO2025014896A1
(en)
|
2023-07-07 |
2025-01-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Humanized 40h3 antibody
|
|
WO2025160480A1
(en)
|
2024-01-26 |
2025-07-31 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Enhanced tumor reactivity of t cells lacking sit1, lax1, or trat1
|
|
WO2025250587A1
(en)
|
2024-05-29 |
2025-12-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Drug-regulatable, inducible cytokine expression
|